Conc at dosing interval [General Sta­tis­tics]

posted by jag009  – NJ, 2013-11-26 18:31 (4591 d 12:48 ago) – Posting: # 11977
Views: 16,770

Hi Helmut,

❝ Yes, that’s a nice one! Currently for EMA BE of MR products has to be demonstrated both after SD and in steady state. Paixão et al.1 showed that for drugs with linear PK Cτ is predictive of steady state.2 We will see whether the mighty oracle will accept this approach and drop the requirement of MD studies in the final guideline.


I never agree to the cancelling of steady state study by FDA because there are some cases where SD study is not entirely sensitive...

John

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
145 visitors (1 registered, 144 guests [including 23 identified bots]).
Forum time: 08:19 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5